AR121804A1 - Preparación sólida y método para producir la misma - Google Patents

Preparación sólida y método para producir la misma

Info

Publication number
AR121804A1
AR121804A1 ARP210100940A ARP210100940A AR121804A1 AR 121804 A1 AR121804 A1 AR 121804A1 AR P210100940 A ARP210100940 A AR P210100940A AR P210100940 A ARP210100940 A AR P210100940A AR 121804 A1 AR121804 A1 AR 121804A1
Authority
AR
Argentina
Prior art keywords
mass
parts
solid preparation
producing
granule
Prior art date
Application number
ARP210100940A
Other languages
English (en)
Inventor
Rie Yamada
Hazuki Omagari
Toshinori Tanaka
Original Assignee
Nippon Shinyaku Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nippon Shinyaku Co Ltd filed Critical Nippon Shinyaku Co Ltd
Publication of AR121804A1 publication Critical patent/AR121804A1/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4965Non-condensed pyrazines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/20Pills, tablets, discs, rods
    • A61K9/28Dragees; Coated pills or tablets, e.g. with film or compression coating
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/08Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Biochemistry (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente descripción proporciona una preparación sólida que contiene 2-{4-[N-(5,6-difenilpirazin-2-il)-N-isopropilamino]butiloxi}-N-(metilsulfonil)acetamida (nombre genérico; “selexipag”); y un método para producir la preparación sólida. La preparación sólida comprende un gránulo que contiene (A) selexipag, (B) almidón, y (C) al menos un aglutinante seleccionado del grupo que consiste en hidroxipropil celulosa e hipromelosa, en donde el componente (B) está presente en una cantidad de 20 partes en masa o más (excluyendo el rango de 30,2 a 30,4 partes en masa) por 100 partes en masa del gránulo, y el componente (C) está presente en una cantidad de 4 partes en masa o menos por 100 partes en masa del gránulo.
ARP210100940A 2020-04-10 2021-04-09 Preparación sólida y método para producir la misma AR121804A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2020071233 2020-04-10

Publications (1)

Publication Number Publication Date
AR121804A1 true AR121804A1 (es) 2022-07-13

Family

ID=78023633

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP210100940A AR121804A1 (es) 2020-04-10 2021-04-09 Preparación sólida y método para producir la misma

Country Status (4)

Country Link
JP (2) JP6989064B1 (es)
AR (1) AR121804A1 (es)
TW (1) TW202203924A (es)
WO (1) WO2021206159A1 (es)

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ742784A (en) * 2015-12-02 2024-08-30 Nippon Shinyaku Co Ltd Pharmaceutical composition containing 2-{ 4-[n-(5,6- diphenylpyrazin-2-yl)-n-isopropylamino]butyloxy} -n- (methylsulfonyl)acetamide
KR20200088382A (ko) * 2017-11-16 2020-07-22 니뽄 신야쿠 가부시키가이샤 방출 제어 제제
CA3091584A1 (en) * 2018-02-21 2019-08-29 Nippon Shinyaku Co., Ltd. Granular composition, production method for granular composition, and dissolution property improvement method for granular composition

Also Published As

Publication number Publication date
WO2021206159A1 (ja) 2021-10-14
JP6989064B1 (ja) 2022-01-05
JPWO2021206159A1 (es) 2021-10-14
TW202203924A (zh) 2022-02-01
JP2022016561A (ja) 2022-01-21

Similar Documents

Publication Publication Date Title
AU2007298751B2 (en) Pharmaceutical compositions containing rosuvastatin calcium
KR102072371B1 (ko) 7-[4-(4-벤조[b]티오펜-4-일-피페라진-1-일)부톡시]-1H-퀴놀린-2-온 또는 그 염을 함유하는 정제
DOP2022000110A (es) Aminoquinolonas sustituidas como inhibidores de dgk alfa para la activación inmune
BRPI0607869A2 (pt) hidroxietilcelulose em bloco, derivados da mesma, processos de fabricação e usos da mesma
BRPI0518553A2 (pt) composiÇço farmacÊutica estÁvel, mÉtodo para estabilizaÇço de pelo menos um ingrediente farmaceuticamente ativo e mÉtodo de uso de celulose microcristalina silicificada
BR112022002496A2 (pt) Compostos deuterados para uso no tratamento de câncer
BR112017023764A2 (pt) derivados de ciclohexano substituído por amido
BR112021022335A2 (pt) Formas cristalinas de n-(3-(2-(2-hidroxietoxi)-6-morfolinopiridin-4-il)-4-metilfenil)-2 (trifluorome-til)isonicotinamida como inibidores raf para o tratamento de câncer
BR112022019057A2 (pt) Aminotiazóis substituídos como inibidores de dgkzeta para ativação imune
EA201992074A1 (ru) Фармацевтическая композиция, содержащая селексипаг
BRPI0717123B8 (pt) cápsulas rígidas de hidroxipropil metil celulose e processo de fabricação
NO20075641L (no) Kroman og kromenderivater og ders anvendelse
BRPI0513858B8 (pt) compostos de benziltriazolona como inibidores não-nucleosídeos da transcriptase reversa, seu processo de preparação, seu uso e composição farmacêutica que os compreende
RU2012103538A (ru) Композиции и способы ингибирования пути jak
HN2008000240A (es) Agentes voluminizadores
ECSP22040921A (es) Composición farmacéutica que comprende selexipag
AR121804A1 (es) Preparación sólida y método para producir la misma
CR20210686A (es) Análogos de 3–(5–metil–1,3–tiazol–2–il)–n–{(1r)–1–[2–(trifluor–metil)pirimidin–5–il]etil}benzamida
CO2024013531A2 (es) Formas sólidas, sales y procesos de preparación de un inhibidor de cdk2
CO2021011023A2 (es) Compuesto heterocíclico, composición farmacéutica que lo comprende, método para su preparación, y uso de estos
BR112022020609A2 (pt) Composição farmacêutica para administração oral que compreende derivado de aminopirimidina ou sal, hidrato ou solvato farmaceuticamente aceitável do mesmo
CO2023005942A2 (es) Composiciones farmacéuticas de un inhibidor de cinasa
BR112022013280A2 (pt) Composição farmacêutica contendo regorafenib e um agente estabilizante
CO2022003346A2 (es) Composiciones de recubrimiento de semillas
BR112022014772A2 (pt) Dispersão sólida amorfa, composição farmacêutica e processos para a preparação destas